PUBLISHER: IMARC | PRODUCT CODE: 1729294
PUBLISHER: IMARC | PRODUCT CODE: 1729294
The Japan gene therapy size reached USD 343.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,133.2 Million by 2033, exhibiting a growth rate (CAGR) of 14.2% during 2025-2033. The escalating prevalence of genetic disorders, recent advancements in gene editing technologies, implementation of supportive policies by the Government of Japan, and the increasing investment in research and development (R&D) represent some of the key factors driving the market.
Gene therapy is a groundbreaking approach in the medical field, designed to address and potentially eradicate diseases through the modification of genes within an individual's cells. This advanced technique encompasses the introduction, deletion, or alteration of genetic material in a patient's cells, with the primary aim of rectifying the genetic anomalies causing various diseases. The essential components of gene therapy include therapeutic deoxyribonucleic acid (DNA), a delivery vector that facilitates the transfer of DNA into cells, and sophisticated gene-editing technologies, such as CRISPR. It finds application across numerous domains, including cancer treatment, management of viral infections, tackling cardiovascular diseases (CVDs), neurological disorders, autoimmune diseases, age-related illnesses, specific types of blindness, and genetic disorders, including hemophilia, cystic fibrosis, and sickle cell disease.
The escalating prevalence of genetic disorders and cancers in Japan, which has prompted the need for innovative treatment methods, such as gene therapy, is propelling the market growth. Additionally, the recent advancements in gene editing technologies such as CRISPR/Cas9, which have improved the accuracy of gene modifications and enhanced the success rates of therapies, are contributing to the market growth. Furthermore, the substantial investments in research and development (R&D) activities by pharmaceutical and biotech companies to develop effective and innovative gene therapies are boosting the market growth. Along with this, the implementation of supportive regulations and policies by the Government of Japan to accelerate approval processes and promote gene therapy trials and products is stimulating the market growth. Besides this, the emergence of advanced vector delivery systems, which improve gene therapy's efficacy and minimize potential side effects, thus ensuring more effective and safer treatment options, is supporting the market growth. Moreover, the heightened awareness about gene therapy and its potential benefits among healthcare professionals and patients is strengthening the market growth. Apart from this, the growing strategic alliances and collaborations among universities, research institutions, and companies to boost innovation and broaden the potential for commercialization are catalyzing the market growth. In addition, the escalating geriatric population, which is highly susceptible to various age-related diseases, such as Parkinson's disease, osteoarthritis, Alzheimer's disease, and age-related macular degeneration (AMD), is fueling the market growth. Other factors, including rising healthcare expenditure, growing adoption of precision medicines, and increasing demand for innovative therapies, are anticipated to drive the market growth.